Cerebriu Apollo Brain

Cerebriu

Key Features

Real-time results enabling mr protocol adaptation
Vizualization of criticial brain pathology candidate findings

General Information

Product name

Cerebriu Apollo Brain

Company

Cerebriu

Subspeciality

Neuro

Modality

Disease targeted

Infarcts (except chronic), intracranial tumors (except iso-intense on T2 FLAIR), and intracranial hemorrhages (except isolated intraventricular hemorrhages, microhemorrhages, or those that are not hypointense on SWI/T2* GRE).

Main task

Not specified

Technical Specifications

Population

Patients between 15 and 75 years receiving brain MR

Patient population age

Not specified

Input

FLAIR, diffusion, T2*/SWI or equivalent

Input format

DICOM

Output

Detection of candidates finding larger than 5 mm3, image annotations

Output format

DICOM SC

Integration

Embedded on the MRI console, Integration via AI marketplace or distribution platform, Stand-alone third party application, Stand-alone webbased

Deployment

Cloud-based, Hybrid solution, Locally on dedicated hardware

Trigger for analysis

Automatically, While the patient is in the scanner

Processing time

1 - 10 minutes

Regulatory Information

CE Certification

Pathway:

MDD

Class:

Class I

Verified by Health AI Register

Other certifications

Not specified

Market Presence

On market since

05-2021

AI Platforms

CARPL.AI, Deepc, Newton's Tree

Resellers

Qure.ai

Countries present

Not specified

Paying clinical customers

Not specified

Research/test users

Not specified

Pricing Information

Pricing model

Subscription

Based on

Number of analyses, Number of installations, Number of users

Evidence & Research

Peer-Reviewed Papers

Peer-Reviewed

View

Diagnostic test accuracy study of a commercially available deep learning algorithm for ischemic lesion detection on brain MRIs in suspected stroke patients from a non-comprehensive stroke center

Source: vendor | First published: Oct 28, 2023 | Last updated: Jul 14, 2025